Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vigil Neuroscience, Inc. (VIGL)

6.48   0.41 (6.75%) 09-27 16:00
Open: 6.07 Pre. Close: 6.07
High: 6.61 Low: 5.7556
Volume: 22,865 Market Cap: 232(M)

Technical analysis

as of: 2023-09-27 4:22:52 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 8.73     One year: 10.2
Support: Support1: 5.75    Support2: 4.68
Resistance: Resistance1: 7.48    Resistance2: 8.73
Pivot: 5.85
Moving Average: MA(5): 5.88     MA(20): 5.87
MA(100): 7.96     MA(250): 9.99
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 55.6     %D(3): 45.1
RSI: RSI(14): 53
52-week: High: 16.77  Low: 4.68
Average Vol(K): 3-Month: 50 (K)  10-Days: 50 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VIGL ] has closed below upper band by 27.8%. Bollinger Bands are 19.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.61 - 6.63 6.63 - 6.65
Low: 5.7 - 5.72 5.72 - 5.75
Close: 6.43 - 6.47 6.47 - 6.51

Company Description

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 26 Sep 2023
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP - Yahoo Finance

Wed, 13 Sep 2023
Healthcare Stocks on the Move Wednesday: RCKT, AWH, VIGL, CDXS, HOTH, YCBD, FLGC, CELZ - InvestorsObserver

Wed, 13 Sep 2023
What is the Market's View on Vigil Neuroscience Inc (VIGL) Stock's Price and Volume Trends Wednesday? - InvestorsObserver

Fri, 08 Sep 2023
Vigil Neuroscience Announces Update on its Small Molecule ... - GlobeNewswire

Tue, 08 Aug 2023
Vigil Neuroscience Reports Second Quarter 2023 Financial Results ... - GlobeNewswire

Mon, 07 Aug 2023
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 36 (M)
Shares Float 9 (M)
% Held by Insiders 10.1 (%)
% Held by Institutions 88.8 (%)
Shares Short 786 (K)
Shares Short P.Month 548 (K)

Stock Financials

EPS -1.73
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.28
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -29.8
Return on Equity (ttm) -49.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.21
Qtrly Earnings Growth 0
Operating Cash Flow -71 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -3.77
PEG Ratio 0
Price to Book value 1.51
Price to Sales 0
Price to Cash Flow -3.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.